Folgen
daniel lavanchy
daniel lavanchy
healthcare consultant
Bestätigte E-Mail-Adresse bei alumnibasel.ch
Titel
Zitiert von
Zitiert von
Jahr
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
D Lavanchy
Journal of viral hepatitis 11 (2), 97-107, 2004
36972004
The global burden of hepatitis C
D Lavanchy
Liver international 29, 74-81, 2009
19312009
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017
18082017
Evolving epidemiology of hepatitis C virus
D Lavanchy
Clinical microbiology and infection 17 (2), 107-115, 2011
18042011
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
C Frank, MK Mohamed, GT Strickland, D Lavanchy, RR Arthur, ...
The Lancet 355 (9207), 887-891, 2000
15142000
Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention
D Lavanchy
Journal of clinical virology 34, S1-S3, 2005
7102005
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ...
Journal of viral hepatitis 21, 34-59, 2014
5302014
Global burden of disease (GBD) for hepatitis C
Global Burden of Hepatitis C Working Group
The Journal of Clinical Pharmacology 44 (1), 20-29, 2004
5012004
Historical epidemiology of hepatitis C virus (HCV) in selected countries
P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ...
Journal of viral hepatitis 21, 5-33, 2014
3842014
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
World Health Organization
J Viral Hepat 6, 35-47, 1999
3561999
WHO report on global surveillance of epidemic-prone infectious diseases
World Health Organization
World Health Organization, 2000
2702000
Strategies to manage hepatitis C virus (HCV) disease burden
H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ...
Journal of viral hepatitis 21, 60-89, 2014
2652014
Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants
D FitzSimons, G François, A Hall, B McMahon, A Meheus, A Zanetti, ...
Vaccine 23 (32), 4158-4166, 2005
1812005
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease: introduction
C Alpers, RD Bloom, F Fabrizi, J Izopet, M Jadoul, E Lindley, P Martin, ...
Kidney International 73 (suppl. 109), S6-S99, 2008
1702008
Hepatitis B virus infection in dentistry: a forgotten topic
N Mahboobi, F Agha‐Hosseini, N Mahboobi, S Safari, D Lavanchy, ...
Journal of viral hepatitis 17 (5), 307-316, 2010
1692010
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B13–14 September, 2002Geneva, Switzerland: Consensus statement (Short version)
TE Jury
Journal of hepatology 38 (4), 533-540, 2003
1682003
Chronic viral hepatitis as a public health issue in the world
D Lavanchy
Best practice & research Clinical gastroenterology 22 (6), 991-1008, 2008
1662008
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B13–14 September, 2002Geneva, Switzerland: Consensus statement (Short version)
TE Jury
Journal of hepatology 38 (4), 533-540, 2003
162*2003
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B13–14 September, 2002Geneva, Switzerland: Consensus statement (Short version)
TE Jury
Journal of hepatology 38 (4), 533-540, 2003
162*2003
Seroprevalence of hepatitis E virus in Switzerland
D Lavanchy, B Morel, PC Frei
The Lancet 344 (8924), 747-748, 1994
1361994
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20